$19.57 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) This Quarter

Brokerages expect that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) will announce sales of $19.57 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Enanta Pharmaceuticals’ earnings. The lowest sales estimate is $16.03 million and the highest is $22.39 million. Enanta Pharmaceuticals reported sales of $21.62 million in the same quarter last year, which indicates a negative year over year growth rate of 9.5%. The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year sales of $87.89 million for the current financial year, with estimates ranging from $78.43 million to $92.48 million. For the next financial year, analysts expect that the firm will report sales of $146.89 million, with estimates ranging from $59.55 million to $346.57 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) last released its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 28.80% and a negative net margin of 122.68%. During the same period last year, the firm posted ($1.09) earnings per share.

A number of equities analysts have commented on the company. Oppenheimer reduced their target price on Enanta Pharmaceuticals from $70.00 to $45.00 and set an “outperform” rating for the company in a report on Friday, May 20th. Roth Capital reduced their target price on Enanta Pharmaceuticals from $101.00 to $70.00 in a report on Wednesday, May 11th. SVB Leerink reduced their target price on Enanta Pharmaceuticals from $58.00 to $44.00 and set a “market perform” rating for the company in a report on Thursday, May 19th. Robert W. Baird dropped their price target on Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday, May 19th. Finally, StockNews.com lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $74.75.

In other news, VP Nathalie Adda sold 32,785 shares of the stock in a transaction on Monday, April 4th. The stock was sold at an average price of $72.18, for a total value of $2,366,421.30. Following the sale, the vice president now directly owns 34,982 shares in the company, valued at $2,525,000.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bruce L. A. Carter sold 6,000 shares of the stock in a transaction on Monday, March 21st. The shares were sold at an average price of $67.83, for a total value of $406,980.00. The disclosure for this sale can be found here. Insiders have sold 113,683 shares of company stock worth $8,084,777 over the last 90 days. 11.74% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. First Manhattan Co. raised its stake in Enanta Pharmaceuticals by 2,820.9% in the third quarter. First Manhattan Co. now owns 969,736 shares of the biotechnology company’s stock valued at $55,090,000 after buying an additional 936,536 shares in the last quarter. Geode Capital Management LLC raised its stake in Enanta Pharmaceuticals by 1.0% in the third quarter. Geode Capital Management LLC now owns 333,793 shares of the biotechnology company’s stock valued at $18,962,000 after buying an additional 3,384 shares in the last quarter. Guggenheim Capital LLC acquired a new stake in Enanta Pharmaceuticals in the third quarter valued at $437,000. Portland Global Advisors LLC raised its stake in Enanta Pharmaceuticals by 21.1% in the fourth quarter. Portland Global Advisors LLC now owns 75,869 shares of the biotechnology company’s stock valued at $5,673,000 after buying an additional 13,234 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. acquired a new stake in Enanta Pharmaceuticals in the fourth quarter valued at $64,000. Institutional investors and hedge funds own 98.87% of the company’s stock.

NASDAQ ENTA opened at $38.72 on Thursday. The stock has a 50-day moving average of $63.64 and a 200 day moving average of $68.78. Enanta Pharmaceuticals has a twelve month low of $37.63 and a twelve month high of $102.00. The stock has a market capitalization of $802.01 million, a price-to-earnings ratio of -7.01 and a beta of 0.64.

Enanta Pharmaceuticals Company Profile (Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Stories